Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: Icotinib and Radiation Timing in EGFR+ NSCLC with Brain Metastases
NCT04058704Phase 3Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04058704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058704.